磷酸西格列汀联合地特胰岛素注射液治疗老年Ⅱ型糖尿病的效果
|
摘要
目的:观察磷酸西格列汀联合地特胰岛素注射液治疗老年Ⅱ型糖尿病(T2DM)的效果。方法:选取110例老年T2DM患者作为研究对象,按治疗方案的不同将其分为观察组和对照组各55例。对照组给予地特胰岛素注射液治疗,观察组在对照组的基础上给予磷酸西格列汀治疗。比较两组血糖达标情况、胰岛素使用剂量、治疗前后各项指标[糖化血红蛋白(HbAlc)、空腹血糖(FBG)、餐后2 h血糖(2 hPG)]水平、体质量[腰臀比(WHR)、体质量指数(BMI)]的变化情况及低血糖发生情况。结果:观察组血糖达标时间明显短于对照组,胰岛素使用剂量明显少于对照组,差异均有统计学意义(P<0.05);治疗后观察组HbAlc、2 hPG水平均明显低于对照组,差异有统计学意义(P<0.05);治疗后两组FBG水平比较,差异无统计学意义(P>0.05);治疗后观察组BMI、WHR明显低于对照组,差异有统计学意义(P<0.05);观察组低血糖发生率9.09%(5/55),明显低于对照组的32.73%(18/55),差异有统计学意义(P<0.05)。结论:磷酸西格列汀联合地特胰岛素注射液治疗老年Ⅱ型糖尿病的效果优于单纯地特胰岛素注射液治疗效果。
Objective: To observe effects of Sitagliptin phosphate combined with Insulin detemir injection on elderly patients with type 2 diabetes(T2 DM). Methods: 110 elderly patients with T2 DM were selected as the subjects, and they were divided into observation group(n=55) and control group(n=55) according to the different treatment options. The control group was treated with Insulin detemir injection, while the observation group was treated with Sitagliptin phosphate on the basis of that of the control group. The situations of the blood glucose level reaching the target value, the insulin dosage, and the indicator levels before and after the treatment [glycated hemoglobin(HbAlc), fasting blood glucose(FBG), postprandial 2 h blood glucose(2 hPG)], the changes of body mass [waist to hip ratio(WHR), body mass index(BMI)] and the occurrence of hypoglycemia were compared between the two groups. Results: The time of the blood glucose level reaching the target value of the observation group was significantly shorter than that of the control group; the insulin dosage was significantly lower than that of the control group; and the differences were statistically significant(P<0.05). The HbAlc and 2 hPG levels in the observation group were significantly lower than those in the control group after the treatment, and the differences were statistically significant(P<0.05). There was no statistical difference in the FBG level between the two groups after the treatment(P>0.05). After the treatment, the BMI and WHR of the observation group were significantly lower than those of the control group, and the differences were statistically significant(P<0.05). The incidence of hypoglycemia in the observation group was 9.09%(5/55), which was significantly lower than that in the control group(32.73%, 18/55), and the difference was statistically significant(P<0.05). Conclusions:Sitagliptin phosphate combined with Insulin detemir injection in the treatment of the elderly patients with T2 DM is superior to single Insulin detemir injection.
Objective: To observe effects of Sitagliptin phosphate combined with Insulin detemir injection on elderly patients with type 2 diabetes(T2 DM). Methods: 110 elderly patients with T2 DM were selected as the subjects, and they were divided into observation group(n=55) and control group(n=55) according to the different treatment options. The control group was treated with Insulin detemir injection, while the observation group was treated with Sitagliptin phosphate on the basis of that of the control group. The situations of the blood glucose level reaching the target value, the insulin dosage, and the indicator levels before and after the treatment [glycated hemoglobin(HbAlc), fasting blood glucose(FBG), postprandial 2 h blood glucose(2 hPG)], the changes of body mass [waist to hip ratio(WHR), body mass index(BMI)] and the occurrence of hypoglycemia were compared between the two groups. Results: The time of the blood glucose level reaching the target value of the observation group was significantly shorter than that of the control group; the insulin dosage was significantly lower than that of the control group; and the differences were statistically significant(P<0.05). The HbAlc and 2 hPG levels in the observation group were significantly lower than those in the control group after the treatment, and the differences were statistically significant(P<0.05). There was no statistical difference in the FBG level between the two groups after the treatment(P>0.05). After the treatment, the BMI and WHR of the observation group were significantly lower than those of the control group, and the differences were statistically significant(P<0.05). The incidence of hypoglycemia in the observation group was 9.09%(5/55), which was significantly lower than that in the control group(32.73%, 18/55), and the difference was statistically significant(P<0.05). Conclusions:Sitagliptin phosphate combined with Insulin detemir injection in the treatment of the elderly patients with T2 DM is superior to single Insulin detemir injection.
引文
[1]李英,朱红霞,王敏哲.沙格列汀联合门冬胰岛素30注射液治疗老年2型糖尿病的临床研究[J].中国临床药理学杂志,2014,30(7):568-570.
[2]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中国糖尿病杂志,2014,30(8):893-942.
[3]孔亚坤,耿秀琴,周艳红,等.甘精胰岛素与西格列汀联用治疗口服降糖药控制不佳的老年2型糖尿病的有效性和安全性[J].中国药师,2016,19(4):695-697.
[4]杨东明,闫萍,何华伟,等.地特胰岛素联合低剂量二甲双胍、阿卡波糖治疗老年2型糖尿病超重与肥胖患者疗效及安全性的观察[J].中国糖尿病杂志,2014,22(2):151-153.
[5]戚蓓蓓,宋文春,江冬梅,等.二肽基肽酶-4抑制剂西格列汀联合二甲双胍治疗2型糖尿病的疗效[J].江苏医药,2016,42(15):1728-1729.
[6]王达莉,曾晓,任碧池,等.基础胰岛素联合二肽基肽酶4抑制剂治疗2型糖尿病患者临床观察[J].中国医学创新,2013,10(15):20-21.
[7]范慧洁.基础胰岛素与二肽基肽酶-4抑制剂联合治疗2型糖尿病的临床观察[J].中国医院用药评价与分析,2015,15(7):913-914.
[2]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中国糖尿病杂志,2014,30(8):893-942.
[3]孔亚坤,耿秀琴,周艳红,等.甘精胰岛素与西格列汀联用治疗口服降糖药控制不佳的老年2型糖尿病的有效性和安全性[J].中国药师,2016,19(4):695-697.
[4]杨东明,闫萍,何华伟,等.地特胰岛素联合低剂量二甲双胍、阿卡波糖治疗老年2型糖尿病超重与肥胖患者疗效及安全性的观察[J].中国糖尿病杂志,2014,22(2):151-153.
[5]戚蓓蓓,宋文春,江冬梅,等.二肽基肽酶-4抑制剂西格列汀联合二甲双胍治疗2型糖尿病的疗效[J].江苏医药,2016,42(15):1728-1729.
[6]王达莉,曾晓,任碧池,等.基础胰岛素联合二肽基肽酶4抑制剂治疗2型糖尿病患者临床观察[J].中国医学创新,2013,10(15):20-21.
[7]范慧洁.基础胰岛素与二肽基肽酶-4抑制剂联合治疗2型糖尿病的临床观察[J].中国医院用药评价与分析,2015,15(7):913-914.